^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    1d
    An herbal formula, SH003 alleviates colorectal cancer through dual targeting of adaptive and innate checkpoints PD-L1/CD47. (PubMed, Cancer Cell Int)
    Our investigation demonstrated that SH003 served as a novel CRC immunotherapy by the dual targeting of adaptive and innate checkpoints, PD-L1/CD47 via the regulation of c-Myc signaling, highlighting that SH003 may be an effective herbal candidate drug for the treatment of CRC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD47 (CD47 Molecule) • IL2 (Interleukin 2) • IL1B (Interleukin 1, beta)
    |
    PD-L1 expression
    1d
    PD-1+CD8+ T cell infiltration complements PD-L1 to predict first-line chemo-immunotherapy outcomes in advanced ESCC. (PubMed, Biomark Res)
    Combined stratification identified the longest PFS in high PD-L1 expression and low PD-1+CD8+ T cell infiltration (8.8 months) and the shortest in low PD-L1 and high PD-1+CD8+ T cell infiltration (3.5 months), supporting PD-1+CD8+ T cell infiltration might as a complementary biomarker to PD-L1. For OS, intratumoral CD8+ T cell density (HR 0.896; p = 0.011), clinical stage (HR 1.570; p = 0.025), and BMI (HR 0.935; p = 0.015) were independent factors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression
    1d
    Immunohistochemical Evaluation of PD-L1 Expression in Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer. (PubMed, Anticancer Agents Med Chem)
    PD-L1 expression may be associated with tumor grade in early-stage endometrioid endometrial cancer. However, its clinical significance remains unclear. These findings may be relevant in the context of fertility- preserving management and require further investigation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    1d
    Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes. (PubMed, J Cutan Pathol)
    Our findings support previous reports on the immune-privileged status of BCC. Contrary to the literature, we could not confirm PD-L1 expression on BCC cells, but rather on the intra- and peritumoral immune cells. Given these results and the literature suggesting a tendency of higher immunoreactivity compared to other BCC subtypes, basosquamous BCC might be a better target for anti-PD-1 therapy as opposed to other subtypes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • SOX9 (SRY-Box Transcription Factor 9) • ITGAX (Integrin Subunit Alpha X)
    |
    PD-L1 expression • PD-L1 negative
    |
    Libtayo (cemiplimab-rwlc)
    1d
    Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. (PubMed, Adv Sci (Weinh))
    Furthermore, the combined use of LPC-LNP-Cd28 effectively eradicates resistance to anti-PD-1 therapy. This study provides a highly translatable, cancer-specific nanomedicine platform, confirming that selectively antagonizing tumor-intrinsic CD28 holds profound promise for advanced cancer immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    1d
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=96, Recruiting, Tang-Du Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab)
    1d
    Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. (PubMed, Pak J Pharm Sci)
    Neoadjuvant nivolumab combined with platinum-based chemotherapy demonstrates favorable pharmacological efficacy, manageable toxicity and biomarker-driven therapeutic response in resectable NSCLC under real-world clinical conditions. These findings support the role of personalized immunopharmacotherapy and reinforce the clinical relevance of biomarker-guided drug selection in modern pharmaceutical oncology.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • PD-L1 overexpression
    |
    Opdivo (nivolumab)
    3d
    Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma. (PubMed, Cancer Treat Rev)
    Recent phase III data have led to approval of perioperative pembrolizumab for patients with PD-L1-positive (CPS ≥ 1)...In addition, potential strategies to optimize treatment efficacy and to overcome resistance mechanisms of CPI therapy are discussed. Further trials are needed to define optimal treatment protocols, determinate the best timing of surgery, and identify reliable biomarkers for patient selection, to guide evidence-based therapeutic decision-making in routine clinical practice.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    3d
    Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. (PubMed, IJU Case Rep)
    Histopathological examination following radical nephrectomy with tumor thrombectomy demonstrated a pathological complete response. Diffuse programmed death-ligand 1 expression on pretreatment biopsy may have been associated with a favorable response to nivolumab plus ipilimumab.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3d
    Spatial organization of the tumor immune microenvironment in LAR+ triple-negative breast cancer. (PubMed, Front Immunol)
    Given the small sample size and the inclusion of immune checkpoint inhibitors in a subset of patients, all of whom achieved pCR, these observations should be considered strictly hypothesis-generating. Larger and more homogeneous cohorts will be required to validate these findings and to determine their potential clinical relevance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • AR (Androgen receptor) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • AR positive
    3d
    Single-EV Analyses Require Rigorous Antibody Qualification: PD-L1 Profiling in Cell Models and Patient Plasma. (PubMed, J Extracell Biol)
    In subsets of all three cancer cohorts, elevated PD-L1+ sEV levels were observed, suggesting potential clinical relevance. While in-depth clinical correlations lie beyond the scope of this study, our findings establish a validated, standardized protocol for IFCM-based single-EV profiling and highlight the central role of antibody quality in ensuring analytical accuracy.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    3d
    Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset. (PubMed, Int J Urol)
    Using a large-scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin-4 expression and basal-like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KDM6A (Lysine Demethylase 6A) • FGF4 (Fibroblast growth factor 4) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • GATA3 (GATA binding protein 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • TP53 mutation • EGFR expression • ARID1A mutation • FGFR3 mutation • RB1 mutation